Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI plus anlotinib maintenance for oligoprogressive EGFR-mutant NSCLC
ChiCTR2100046562Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started May 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046562.